Dehydroepiandrosterone reduces cancellous bone osteopenia in ovariectomized rats

Area of Science:

• Endocrinology
• Bone Biology
• Skeletal Physiology

Background:

• Ovariectomy in rats mimics postmenopausal osteoporosis.
• Dehydroepiandrosterone (DHA) is an androgen precursor with potential bone-protective effects.
• Reduced circulating DHA levels are observed following ovariectomy.

Purpose of the Study:

• To investigate the impact of DHA on cortical and cancellous bone in intact and ovariectomized rats.
• To determine if DHA supplementation can mitigate ovariectomy-induced bone loss.
• To assess DHA's effects on bone formation and structural changes.

Main Methods:

• Ovariectomy was performed on rats.
• Rats received monthly subcutaneous implants of DHA or placebo.
• Plasma DHA levels were measured.
• Bone morphometry of the tibial diaphysis (cortical bone) and metaphysis (cancellous bone) was analyzed.
• Bone formation rates at periosteal and endosteal surfaces were assessed.

Main Results:

• Ovariectomy led to reduced plasma DHA levels and severe cancellous bone osteopenia.
• DHA treatment normalized plasma DHA in ovariectomized rats and reduced cancellous bone loss.
• Cortical bone area and cross-sectional area at the diaphysis increased post-ovariectomy, unaffected by DHA.
• DHA treatment appeared to counteract the decrease in bone formation at the tibial diaphysis observed 16 weeks after ovariectomy.

Conclusions:

• Decreased peripheral DHA levels are implicated in the skeletal deterioration seen in ovariectomized rats.
• DHA supplementation demonstrates potential therapeutic benefits for bone health, particularly in preventing cancellous bone loss.
• DHA may play a role in regulating bone formation processes affected by ovariectomy.